Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vismodegib

FDA-approved product (capsule, oral), marketed as Erivedge.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Vismodegib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Basal cell carcinoma
  • Cancer
  • Neoplasm
  • Skin basal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hedgehog pathway inhibitors
FDA pharmacologic class
Hedgehog Pathway Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vismodegib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vismodegib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

    NCT01772290 · start 2013-02

    Registered record
    Registry ID
    NCT01772290
    Conditions
    Healthy Volunteer
    Interventions
    fluconazole; itraconazole; rabeprazole; vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-05
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    Interventionfluconazole; itraconazole; rabeprazole; vismodegib
    PhasePhase 1
    Registry statusCompleted

  • Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer

    NCT01713218 · start 2012-12

    Registered record
    Registry ID
    NCT01713218
    Conditions
    Pancreatic Adenocarcinoma Resectable
    Interventions
    gemcitabine; Vismodegib; Neoadjuvant chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2016-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma Resectable
    Interventiongemcitabine; Vismodegib; Neoadjuvant chemotherapy
    PhaseEarly phase 1
    Registry statusUnknown

  • Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

    NCT01556009 · start 2012-04

    Registered record
    Registry ID
    NCT01556009
    Conditions
    Basal Cell Nevus Syndrome; Gorlin's Syndrome
    Interventions
    Vismodegib; Aminolevulinic acid %20 topical solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Nevus Syndrome; Gorlin's Syndrome
    InterventionVismodegib; Aminolevulinic acid %20 topical solution
    PhasePhase 2
    Registry statusCompleted

  • STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

    NCT01367665 · start 2011-07-01

    Registered record
    Registry ID
    NCT01367665
    Conditions
    Basal Cell Carcinoma
    Interventions
    vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07-01
    Completion
    2017-06-14
    Enrolment
    1,232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    Interventionvismodegib
    PhasePhase 2
    Registry statusCompleted

  • Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

    NCT01096732 · start 2011-02

    Registered record
    Registry ID
    NCT01096732
    Conditions
    Pancreatic Ductal Adenocarcinoma
    Interventions
    GDC-0449
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2012-08
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Adenocarcinoma
    InterventionGDC-0449
    PhasePhase 2
    Registry statusTerminated

  • A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

    NCT01201915 · start 2010-10

    Registered record
    Registry ID
    NCT01201915
    Conditions
    Basal Cell Carcinoma
    Interventions
    Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10
    Completion
    2013-05
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionVismodegib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects

    NCT01173536 · start 2010-08-25

    Registered record
    Registry ID
    NCT01173536
    Conditions
    Healthy Volunteer
    Interventions
    GDC-0449; moxifloxacin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08-25
    Completion
    2011-03-18
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionGDC-0449; moxifloxacin; placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

    NCT01160250 · start 2010-07

    Registered record
    Registry ID
    NCT01160250
    Conditions
    Basal Cell Carcinoma
    Interventions
    vismodegib (GDC-0449)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    2010-07
    Completion
    2012-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    Interventionvismodegib (GDC-0449)
    PhaseNot recorded
    Registry statusApproved for marketing

  • Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

    NCT01154452 · start 2010-06

    Registered record
    Registry ID
    NCT01154452
    Conditions
    Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Mesenchymoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Unclassified Pleomorphic Sarcoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Dermatofibrosarcoma Protuberans; Gastrointestinal Stromal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Ovarian Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Kaposi Sarcoma; Recurrent Osteosarcoma; Recurrent Uterine Corpus Sarcoma; Small Intestine Leiomyosarcoma
    Interventions
    Gamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacological Study; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2015-02
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma +26 more
    InterventionGamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacological Study; Vismodegib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

    NCT01195415 · start 2010-06

    Registered record
    Registry ID
    NCT01195415
    Conditions
    Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer
    Interventions
    Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2014-10-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer
    InterventionGemcitabine Hydrochloride; Laboratory Biomarker Analysis; Vismodegib
    PhasePhase 2
    Registry statusCompleted

  • RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

    NCT01071564 · start 2009-11

    Registered record
    Registry ID
    NCT01071564
    Conditions
    Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma
    Interventions
    Gamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacogenomic Study; Pharmacological Study; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2014-06
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma +4 more
    InterventionGamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacogenomic Study; Pharmacological Study +1 more
    PhasePhase 1
    Registry statusTerminated

  • Evaluation of Food Effect on Pharmacokinetics of Vismodegib

    NCT01174264 · start 2009-10

    Registered record
    Registry ID
    NCT01174264
    Conditions
    Malignant Neoplasm
    Interventions
    Pharmacological Study; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2014-12
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionPharmacological Study; Vismodegib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

    NCT00959647 · start 2009-09-03

    Registered record
    Registry ID
    NCT00959647
    Conditions
    Ovarian Cancer; Basal Cell Carcinoma; Metastatic Colorectal Cancer
    Interventions
    Vismodegib; FOLFOX; FOLFIRI; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09-03
    Completion
    2014-01-09
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Basal Cell Carcinoma; Metastatic Colorectal Cancer
    InterventionVismodegib; FOLFOX; FOLFIRI; Bevacizumab
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

    NCT00991718 · start 2009-09

    Registered record
    Registry ID
    NCT00991718
    Conditions
    Healthy
    Interventions
    GDC-0449 oral capsules (non-labeled); GDC-0449 IV injection (labeled); CDC-0449 oral suspension (labeled)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGDC-0449 oral capsules (non-labeled); GDC-0449 IV injection (labeled); CDC-0449 oral suspension (labeled)
    PhasePhase 1
    Registry statusCompleted

  • To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

    NCT00957229 · start 2009-08

    Registered record
    Registry ID
    NCT00957229
    Conditions
    Basal Cell Nevus Syndrome; Gorlin Syndrome
    Interventions
    GDC-0449
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-08
    Completion
    2014-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Nevus Syndrome; Gorlin Syndrome
    InterventionGDC-0449
    PhasePhase 2
    Registry statusCompleted